CYP11B1
Cytochrome P450 11B1, mitochondrial
As of the edition of 20 October 2026, CYP11B1 (cytochrome P450 11B1, mitochondrial, UniProt P15538) has 5 drugs tested at it and 11 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P15538
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Cancer; Hormones; Urinary and reproductive; Nutrition and metabolism; Infections; Skin and connective tissue; Immune system; Pregnancy and women's health
- Registered trials of its drugs
- 194
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ketoconazole | Marketed | Phase 4 | none listed |
| Osilodrostat | Marketed | Phase 4 | Ends 2033 |
| Metyrapone | Marketed | Phase 4 | none listed |
| Mitotane | Marketed | Phase 3 | none listed |
| Levoketoconazole | Marketed | Phase 3 | Ends 2028 |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 3 |
| Undetermined | 6 |
| Total on the list | 11 |
| Company | Route |
|---|---|
| Esteve Pharmaceuticals | Route B |
| Cortendo | Route B |
The other 9 companies at CYP11B1
In the product11 companies in all; 9 are not named here, and no score is.
See the 11 companies at CYP11B1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.